How should metabolic acidosis associated with a propofol infusion be managed, including when to discontinue propofol and what supportive measures to implement?

Management of Propofol-Associated Metabolic Acidosis

If metabolic acidosis develops during propofol infusion, immediately discontinue propofol and transition to alternative sedation, as this may represent propofol infusion syndrome (PRIS)—a life-threatening condition with mortality up to 33%. 1, 2

Recognition and Immediate Action

Clinical Presentation of PRIS

Propofol infusion syndrome presents with:

• Worsening metabolic acidosis (high anion gap, base excess >10 mmol/L)
• Hypertriglyceridemia
• Hypotension with increasing vasopressor requirements
• Cardiac arrhythmias (bradycardia, atrial fibrillation, bundle branch block, asystole)
• Rhabdomyolysis with elevated creatine kinase and myoglobinuria
• Acute kidney injury
• Hyperkalemia
• Hepatomegaly and liver dysfunction 1, 2, 3, 4

Critical Decision Point

The variable presentation and lack of diagnostic specificity make early recognition difficult, but early detection and propofol discontinuation are critically important. 1 The syndrome can progress rapidly from metabolic acidosis to cardiovascular collapse and death, even after stopping the infusion. 1

Risk Factors to Monitor

High-risk scenarios include:

• Propofol doses >70 μg/kg/min (>5 mg/kg/h) for >48 hours 1, 2, 4
• However, PRIS can occur with low-dose infusions and even during short-term surgical anesthesia 1, 4, 5
• Decreased oxygen delivery to tissues
• Serious neurological injury or sepsis
• Concomitant high-dose vasoconstrictors, steroids, or inotropes
• Carbohydrate depletion
• Underlying mitochondrial disorders 2, 3, 6

Common pitfall: Clinicians often fail to recognize PRIS at lower doses or shorter durations. The incidence is approximately 1%, but mortality reaches 33%. 1

Immediate Management Algorithm

Step 1: Discontinue Propofol Immediately

• Stop propofol infusion as soon as PRIS is suspected—do not wait for confirmatory testing 1, 2, 3
• Avoid abrupt discontinuation in stable patients without PRIS, as this causes rapid awakening with anxiety and ventilator resistance 2

Step 2: Transition to Alternative Sedation

Switch to:

• Dexmedetomidine (0.2-0.7 μg/kg/h) as first-line alternative 7
• Benzodiazepines (midazolam 1-8 mg/h) if dexmedetomidine contraindicated 7
• Maintain analgesic-first approach with fentanyl (25-300 μg/h) 7

Step 3: Supportive Management

• Cardiovascular support: Aggressive fluid resuscitation, vasopressors, inotropes as needed 2, 3
• Correct metabolic acidosis: Sodium bicarbonate administration 8, 9
• Renal replacement therapy: Consider hemodialysis or hemofiltration to remove propofol and toxic metabolites 3, 8, 9
• Extracorporeal membrane oxygenation (ECMO): For refractory cardiac failure 3
• Artificial ventilation with oxygen: For respiratory depression 2

Monitoring During Propofol Use

Routine Laboratory Surveillance

Monitor these parameters during prolonged propofol infusions:

• Arterial blood gases (pH, pCO2, base excess)
• Lactate levels
• Creatine kinase (CK)
• Serum triglycerides (propofol contains 0.1 g fat/mL = 1.1 kcal/mL)
• Electrolytes (particularly potassium)
• Renal function (creatinine, BUN)
• Liver enzymes
• Troponin I 2, 3, 4, 9, 10

Recent evidence: A 2025 cohort study of 235 status epilepticus patients found propofol associated with lipid dysregulation (elevated triglycerides, decreased LDL/HDL), impaired renal function, mild respiratory acidosis, and pro-inflammatory markers (elevated CRP, procalcitonin, leukocytes). 10

Clinical Warning Signs

In the setting of prolonged propofol use, increasing dose requirements to maintain sedation or onset of metabolic acidosis should prompt consideration of alternative sedation. 2

Prevention Strategies

Dose and Duration Limits

• Avoid doses >5 mg/kg/h (>70 μg/kg/min) for >48 hours 1, 2, 4
• Consider alternative sedatives for prolonged ICU sedation 3, 8
• The FDA label specifically warns about PRIS risk with prolonged high-dose infusions 2

Alternative Sedation Approaches

For ICU sedation requiring >48 hours:

• Dexmedetomidine preferred over propofol for lighter sedation targets 7, 11, 12
• Analgesic-first approach with fentanyl, adding sedatives only as needed 7
• Intermittent benzodiazepines rather than continuous infusions in select cases 12

Special Populations

Contraindications for propofol:

• Patients with known mitochondrial disorders (absolute contraindication) 6
• Egg, soy, or sulfite allergies 13
• Hemodynamically unstable patients (relative contraindication—propofol causes dose-dependent hypotension) 1, 13

Pathophysiology Context

PRIS results from:

• Mitochondrial dysfunction: Impaired fatty acid β-oxidation
• Disruption of electron transport chain: Reduced complex IV and cytochrome oxidase activity
• Metabolic derangements: Diversion of carbohydrate metabolism to fat substrates
• Propofol metabolite accumulation 1, 3, 4

This explains why patients with underlying mitochondrial disease are at extreme risk. 6

Key Clinical Pearls

• PRIS is rare (1% incidence) but has 33% mortality—prevention through dose limitation is paramount 1
• Unexplained metabolic acidosis during propofol infusion = PRIS until proven otherwise 8, 9
• Do not wait for full syndrome manifestation—early acidosis alone warrants propofol discontinuation 1, 2
• Lipid administration is NOT recommended for PRIS treatment (unlike local anesthetic toxicity)
• Daily sedation assessment and titration to minimum effective dose reduces PRIS risk 2
• Recent 2023 guidelines recommend propofol primarily for induction phase of targeted temperature management, with transition to lighter sedation during maintenance 7